FMP
NASDAQ
2.34 USD
-0.03 (-1.28%)
Mr. David J. Lennon Ph.D.
Healthcare
Biotechnology
https://aadibio.com
NASDAQ
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
0001422142
US00032Q1040
00032Q104
17383 Sunset Boulevard
424 473 8055
US
89
Feb 16, 2018
0001422142
NASDAQ
Biotechnology
Healthcare
00032Q104
US00032Q1040
US
2.34
0.23
415.86k
57.46M
-
1.55-8.65
-0.14
-
-
-
-
-0.96
-
https://aadibio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.